Liver Cirrhosis (Hepatic Cirrhosis)

Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.

Also Known As:

Networked: 14085 relevant articles (628 outcomes, 1679 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Fibrosis (Cirrhosis)
2.	Hepatocellular Carcinoma (Hepatoma)
3.	Portal Hypertension
4.	Infection
5.	Hemorrhage

Experts

1.	Trautwein, Christian: 52 articles (09/2015 - 06/2002)
2.	Liu, Ping: 48 articles (07/2015 - 08/2002)
3.	Brenner, David A: 46 articles (11/2015 - 01/2003)
4.	Sakaida, Isao: 46 articles (10/2015 - 01/2003)
5.	Tacke, Frank: 41 articles (09/2015 - 06/2002)
6.	Yoshiji, Hitoshi: 32 articles (03/2015 - 07/2002)
7.	Li, Jun: 31 articles (12/2015 - 05/2006)
8.	Fukui, Hiroshi: 31 articles (03/2015 - 07/2002)
9.	Weiskirchen, Ralf: 29 articles (12/2014 - 06/2002)
10.	Maehara, Yoshihiko: 28 articles (08/2015 - 01/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Liver Cirrhosis:

1.	Carbon Tetrachloride (Tetrachloromethane)IBA 09/01/2014 - "To study the protective effects of HSYA on liver fibrosis induced by carbon tetrachloride (CCl4) and a high-fat diet (HFD), and to determine the mechanism of action of HSYA. " 09/01/2015 - "These observations are recapitulated in the well-established carbon tetrachloride model of liver fibrosis in which EphB2(-/-) carbon tetrachloride-treated mice showed a significant reduction of liver fibrosis compared to carbon tetrachloride-treated littermate mice. " 01/01/2015 - "In this study, we investigated their in vivo capabilities of homing and hepatocyte differentiation and therapeutic efficacy for liver disorders in carbon tetrachloride (CCl4)-induced liver fibrosis model mice. " 01/01/2014 - "This study aimed to investigate the therapeutic efficacy of bone marrow (BM)-derived MSCs and SIMV on carbon tetrachloride (CCl4)-induced liver fibrosis in rats. " 11/01/2015 - "Mesenchymal stem cells: In vivo therapeutic application ameliorates carbon tetrachloride induced liver fibrosis in rats."
2.	CollagenIBA 11/01/2009 - "Concluding, HF improved the histology and serum biochemistry of liver cirrhosis, with an important reduction of interstitial collagen and increased extracelullar matrix degradation by reducing profibrotic gene expression." 06/01/2015 - "Mice receiving dietary CPS after BDL had a significant improvement of liver fibrosis accompanied by a decrease in collagen deposition and downregulation of activation markers in isolated HSCs. " 09/01/1999 - "Using in vivo fluorescence microscopy, characteristic microvascular features of CCl(4)-induced liver fibrosis, progressively observed within the 8-week period of toxin exposure, were the significant reduction in sinusoidal density; the increase of venular vascular space; the perivenular accumulation of Ito cells, with concomitant collagen deposition; and the collapse of parenchymal tissue. " 01/01/1991 - "Thus pharmacological inhibition of collagen deposition is likely to be beneficial for patients suffering from fibrotic disorders such as liver cirrhosis. " 04/01/1994 - "It was concluded that a heavy dosage of Paeonia rubra was effective in arresting the development of liver fibrosis, and in promoting the reabsorption of collagen fibres."
3.	Biological Markers (Surrogate Marker)IBA 10/01/2009 - "Noninvasive serum markers offer considerable promise in their ability to stage liver fibrosis. " 08/01/2014 - "Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar." 02/01/2012 - "Histopathological examination, estimation of biochemical markers, and grading of liver fibrosis was performed to evaluate pharmacodynamic efficacy of prepared formulation. " 01/01/2011 - "Liver biopsy represents the gold standard for damage evaluation, but noninvasive serum markers that mirror liver fibrosis progression are actual goals both in adults and especially in children. " 12/08/2006 - "In combination with clinical signs, ultrasound and biochemical markers noninvasive diagnosis of liver cirrhosis will be further improved."
4.	InterferonsIBA 01/01/2008 - "The aim of this study was to elucidate the efficacy of interferon (IFN) therapy in liver cirrhosis Japanese patients with genotype 1b and low virus load. " 12/01/2012 - "This work studied the impact of liver fibrosis on the efficacy of interferon in treating HCV." 01/01/2008 - "The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load." 10/01/2014 - "In total 184 of 466 patients (39.5%) did not receive interferon-based therapy during the study period, with treatment withheld most frequently due to multiple clinical characteristics including hepatic cirrhosis (16.3%), thrombocytopaenia (16.3%) and age >60 years (10.9%). " 12/01/2013 - "This study confirms that the rate of liver fibrosis regression increases during the follow-up after SVR to interferon therapy in HIV-/HCV-coinfected patients."
5.	Thioacetamide (Thioacetamid)IBA 06/20/2015 - "Compared with TA-S, TA-Gb-NPs significantly improved serum biochemical parameters in thioacetamide (TAA) induced liver fibrosis mouse model. " 05/25/2010 - "Histological analysis revealed that ginsenoside-Rg1 significantly improved the extent of liver fibrosis in rats induced by thioacetamide. " 01/01/2013 - "Rats with thioacetamide-induced liver cirrhosis were injected with the chimera to evaluate therapeutic efficacy. " 09/01/2008 - "This is the first study to demonstrate that knockdown of hepatic SPARC expression ameliorates thioacetamide-induced liver fibrosis in rats with chronic liver injury. " 05/01/2015 - "Rat liver fibrosis was induced with thioacetamide and the degree of liver fibrosis was determined using pathological diagnosis as a gold standard. "
6.	Lamivudine (3TC)FDA Link 12/01/2003 - "Whether long-term lamivudine therapy is effective in HBV-related liver cirrhosis patients was prospectively evaluated. " 06/01/2006 - "The improvement in serum ALT and CP score at week 48 was similar irrespective of baseline decompensation, liver cirrhosis and the duration of overlap lamivudine therapy. " 09/15/2015 - "A proportion of HIV/HBV-coinfected patients on long-term lamivudine-containing ART had poor HIV and HBV suppression, drug resistance, and TE values indicative of advanced liver fibrosis. " 01/01/2007 - "Fifty-four patients (Child-Pugh A/B/C, 35/9/10) with HBV-related liver cirrhosis who had been treated with lamivudine for more than 12 months were evaluated. " 07/01/2006 - "The differences remained significant when only liver cirrhosis patients without HCC at presentation were analyzed, but the AUC of the two scores became comparable when patients on lamivudine were excluded. "
7.	Ribavirin (Virazole)FDA LinkGeneric 01/01/2005 - "In conclusion, efficacy of combination therapy with IFNalpha and ribavirin in patients with liver cirrhosis is less effective and should be considered in chosen situations, especially in younger patients. " 01/01/2014 - "Clinical trials in HCV genotype 2/3 patients have demonstrated optimal efficacy in HCV-2, where the combination SOF/ribavirin (Rbv) for 12 weeks resulted in >90% sustained virological response (SVR) rates, while HCV-3 patients with advanced liver fibrosis and previous failure to PegIFN plus Rbv therapy still require individualized and optimized treatment strategies. " 08/28/2013 - "In the study's first part, 10 participants with early to moderate liver fibrosis were treated with 400 mg/d of sofosbuvir and weight-based ribavirin for 24 weeks. " 12/01/2015 - "Antiviral regimens including sofosbuvir are associated with success rates >90%, even in the case of "difficult-to-treat" patients such as subjects with liver cirrhosis as well as prior null response to IFN and ribavirin. " 01/01/2015 - "Inclusion criteria were HIV/HCV coinfection with advanced liver fibrosis and documented previous treatment failure on peginterferon-ribavirin. "
8.	Non-alcoholic Fatty Liver DiseaseIBA 12/21/2011 - "IKK2 inhibitor IMD markedly improved non-alcoholic fatty liver disease in mice by lowering NF-κB activation, which could become a remedial target for liver fibrosis." 01/01/2011 - "Our results show that patients with biopsy-proven NAFLD have a significant reduction in serum sVEGFR-1 concentrations that predict the degree of liver fibrosis, independent of potential confounders." 01/01/2011 - "Liver stiffness measurement (LSM) is a noninvasive and reliable method for the indirect evaluation of liver fibrosis, but it may be less effective in case of nonalcoholic fatty liver disease (NAFLD). " 11/01/2015 - "In this study, we confirmed that serum Fuc-Hpt is suitable for the prediction of ballooning hepatocytes and that serum Mac2bp is suitable for the prediction of liver fibrosis severity in 124 biopsy-proven NAFLD patients (training cohort). " 03/01/2015 - "In our study we aimed to investigate whether the severity of liver fibrosis estimated with the NFS is associated with a higher risk of CHD among individuals with ultrasonography-diagnosed NAFLD. "
9.	Hepatitis B Surface Antigens (HBsAg)FDA Link 07/15/2005 - "Our study showed that long-term hepatic complications occur in a significant proportion of HBsAg+ patients after HSCT and the incidence of liver cirrhosis is reduced in those with sustained serologic clearance of HBsAg after HSCT." 06/01/2009 - "Liver fibrosis improved in 70% of patients with HBsAg seroconversion compared to 30% of those without HBsAg seroconversion (p < 0.01). " 01/01/2009 - "Liver cirrhosis and HCC are relatively prevalent, and 80% to 85% of the patients with these conditions have positive results for hepatitis B surface antigen in Taiwan. " 07/01/2014 - "A total of 2,139 HBsAg-seropositive, anti-HCV-seronegative, and treatment-naïve participants without liver cirrhosis at study entry were included. " 10/01/2012 - "The aim of this study was to determine the dynamic expression profile of hepatitis B surface antigen (HBsAg) according to hepatic parenchyma cells' volume at different stages of liver fibrosis during the immune clearance phase. "
10.	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/01/2009 - "We previously reported successful therapy of liver cirrhosis in rats using the hepatocyte growth factor gene. " 03/01/2010 - "Administration of exogenous hepatocyte growth factor (HGF) may be potentially useful for the treatment of liver fibrosis. " 03/01/2000 - "Hepatocyte growth factor gene therapy may have the potential to be useful for the treatment of patients with liver cirrhosis." 01/01/2015 - "Adenoviral delivery of truncated MMP-8 fused with the hepatocyte growth factor mutant 1K1 ameliorates liver cirrhosis and promotes hepatocyte proliferation." 08/01/2014 - "In this study, we demonstrate that hepatocyte growth factor (HGF), an antifibrotic factor in the process of pulmonary, renal and liver fibrosis, is a negative regulator of cardiac fibroblast transformation in response to transforming growth factor‑β1 (TGF‑β1). "

Therapies and Procedures

1.	Transplantation (Transplant Recipients) 07/07/2001 - "For patients with cirrhosis, liver transplantation for HCC with one nodule less than 5 cm in diameter, or no more than three nodules each less than 3 cm, gives the best results with a 5-year survival rate of 70%. " 07/01/2012 - "Mice with BMSC transplantation with continuous CCl 4 injection had reduced liver fibrosis and a significantly improved expression of albumin compared with mice treated with CCl 4 alone. " 03/01/2015 - "Mesenchymal stem cell (MSC) transplantation was shown to be effective for the treatment of liver fibrosis, but the mechanisms of action are not yet fully understood. " 04/01/2013 - "Targeting AR, a key factor in male sexual phenotype, in BM-MSCs improves transplantation therapeutic efficacy for treating liver fibrosis." 12/01/2005 - "Should the patient progress to decompensated cirrhosis, liver transplantation is an effective treatment for AIH. "
2.	Liver Transplantation 05/18/2015 - "Liver transplantation (LT) provides the best chance of cure for patients with HCC and liver cirrhosis. " 06/01/2010 - "Liver transplantation has been the most effective treatment for patients with hepatic cirrhosis. " 08/01/2015 - "Between 2010-2011, 81 consecutive individuals with confirmed hepatic cirrhosis who were a candidate for liver transplantation were enrolled in this study. " 07/01/2015 - "A prospective single-center study investigated 174 patients undergoing liver transplantation due to acute decompensation of hepatitis B virus (HBV)-associated liver cirrhosis. " 04/01/2014 - "The aim of the study was to evaluate liver fibrosis by the ARFI with correlation of pathological stages in living donor liver transplantation (LDLT). "
3.	Splenectomy 03/01/2015 - "Therapeutic efficacy of splenectomy is attenuated by necroinflammation of the liver in patients with liver cirrhosis." 10/01/2014 - "We examined whether splenectomy improved liver fibrosis and caused immunological changes. " 04/01/1967 - "[The efficacy of splenectomy and portacaval tissue anastomoses in patients with liver cirrhosis]." 10/01/2015 - "Although studies have shown that splenectomy suppresses liver fibrosis, the mechanism by which this occurs is poorly understood. " 02/01/2014 - "The aim of the present study was to evaluate the long-term effects of splenectomy and subsequent IFN therapy in patients with hepatitis C virus (HCV)-related liver cirrhosis (LC). "
4.	Transplants (Transplant) 01/24/2015 - "After 6 more weeks of CCl4 injection (12 weeks in all), nude mice with hADMPCs transplants exhibited a significant reduction in liver fibrosis, as evidenced by Sirius Red staining, compared with nude mice treated with CCl4 for 12 weeks without hADMPCs transplants. " 09/01/2010 - "For the diagnosis of significant liver fibrosis in HCV transplant patients, the transient elastography reaches good results but cannot replace liver biopsy. " 09/01/2015 - "Doppler Ultrasound and Transient Elastography in Liver Transplant Patients for Noninvasive Evaluation of Liver Fibrosis in Comparison with Histology: A Prospective Observational Study." 05/14/2012 - "Recent studies have shown that post-liver transplant, there is a link between high levels of HCV replication, enhanced hepatocyte apoptosis and the subsequent development of rapidly progressive liver fibrosis. " 12/01/2006 - "We used DC-MRI to study 67 patients suffering from hepatic cirrhosis and on a waiting list for liver transplant. "
5.	Hepatectomy 04/01/2005 - "BCAA supplementation after hepatectomy promotes rapid improvement in protein metabolism and inhibits progression to liver cirrhosis. " 02/01/1998 - "The HGF administration significantly improved liver fibrosis at the time of operation, attenuated the postoperative hepatic damage on histological examination, markedly accelerated the liver regeneration at 24 h after the hepatectomy. " 04/01/2006 - "We demonstrated the therapeutic efficacy of adenovirus-mediated HGF and TbetaTR gene transduction after partial hepatectomy for liver cirrhosis. " 01/01/1978 - "In the presence of a TAA-induced liver cirrhosis, liver regeneration 7 days after PCS and 70% hepatectomy is not improved by additional arterialization of the portal vein." 05/01/2011 - "The aim of this study was to assess the effect of preoperative and postoperative synbiotic treatment in hepatectomy patients with or without liver cirrhosis. "